News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hisamitsu Pharmaceutical , Nippon Shinyaku Co., Ltd. Conclude Joint Development Agreement For HFT-290 Cancer Pain Palliative Care Agent


10/19/2005 5:13:14 PM

Tokyo (JCNN) - Hisamitsu Pharmaceutical and Nippon Shinyaku (TSE: 4516) announced on April 7 that they have entered into a joint development agreement for HFT-290, a drug candidate for the treatment of cancer pain. The two companies will conduct Phase III clinicalt trials, and co-promote the new product in Japan.

Read at JCN Newswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES